Efter endt behandling medførte afbrydelsen af behandling med CHAMPIX, at op til 3% af patienterne oplevede øget irritabilitet, rygetrang, depression og/ eller søvnløshed.
At the end of treatment, discontinuation of CHAMPIX was associated with an increase in irritability, urge to smoke, depression, and/ or insomnia in up to 3% of patients.